PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 44-50

  Duman, Berna Bozkurt ^a   Sahin, B ^a   Acikalin, A ^a   Ergin, M ^a   Zorludemir, S ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Akt; Breast cancer; MAPK; p53; p95; PTEN

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; P95 PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOADJUVANT THERAPY; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879029656     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/-neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
2. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-984. (Pubitemid 47050487)
3. Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005; 6:77-80. (Pubitemid 40872949)
4. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004; 5: 81-96. (Pubitemid 38072721)
5. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-3105. (Pubitemid 34791099)
6. Fornier M, Risio M, Van PC, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002; 16: 1340-1342.
7. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-3664.
8. Scaltriti M., Rojo F., Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-638. (Pubitemid 47073544)
9. Chandarlapaty S, Sakr RA, Giri D et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012 Oct 23. [Epub ahead of print].
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127. (Pubitemid 39485684)
13. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
14. Joensuu H, Kellokumpu-Lehtinen PL. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820. (Pubitemid 43290919)
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
16. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684. (Pubitemid 41464706)
17. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749. (Pubitemid 38771819)
18. Nahta R, Esteva FJ. Herceptin. Mechanisms of action and resistance. Cancer Lett 2006;232:123-138.
19. Pegram MD. Can we circumvent resistance to ErbB2- targeted agents by targeting novel pathways? Clin Breast Cancer 2008;8 (Suppl 3):S121-S130.
20. Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004;351:2337-2338. (Pubitemid 39552753)
21. Dave B, Migliaccio I, Gutierrez MC et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-173.
22. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559. (Pubitemid 40490050)
23. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010;21:255-262.
24. Shojaei S, Gardaneh M, Rahimi Shamabadi A. Target points in trastuzumab resistance. Int J Breast Cancer 2012; 761917.
25. Gallardo A, Lerma E, Escuin D et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012;106:1367-1373.
26. Yonemori K, Tsuta K, Shimizu C et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009;26:344-349.
27. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-56. (Pubitemid 30064975)
28. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res 2011;71:1515-1519.